[HTML][HTML] Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and
durable responses in multiple myeloma. However, relapse following therapy is frequently …
durable responses in multiple myeloma. However, relapse following therapy is frequently …
[HTML][HTML] Genome instability in multiple myeloma: Facts and factors
Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
Single-cell profiling in multiple myeloma: insights, problems, and promises
In a short time, single-cell platforms have become the norm in many fields of research,
including multiple myeloma (MM). In fact, the large amount of cellular heterogeneity in MM …
including multiple myeloma (MM). In fact, the large amount of cellular heterogeneity in MM …
[HTML][HTML] Multiple myeloma: the (r) evolution of current therapy and a glance into the future
KC Anderson - Haematologica, 2020 - ncbi.nlm.nih.gov
Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …
[HTML][HTML] Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma …
W Li, B Zhang, W Cao, W Zhang, T Li, L Liu… - … Hematology & Oncology, 2023 - Springer
Abstract Background BCMA CAR-T is highly effective for relapsed/refractory multiple
myeloma (R/R-MM) and significantly improves the survival of patients. However, the short …
myeloma (R/R-MM) and significantly improves the survival of patients. However, the short …
[HTML][HTML] Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma
Multiple myeloma (MM) is a heterogeneous disease characterized by significant genomic
instability. Recently, a causal role for the AID/APOBEC deaminases in inducing somatic …
instability. Recently, a causal role for the AID/APOBEC deaminases in inducing somatic …
Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group
PURPOSE Multiple myeloma (MM) is accompanied by heterogeneous somatic alterations.
The overall goal of this study was to describe the genomic landscape of myeloma using …
The overall goal of this study was to describe the genomic landscape of myeloma using …
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM),
yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational …
yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational …
PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation
Dysregulation of polycomb repressive complex 2 (PRC2) promotes oncogenesis partly
through its enzymatic function for inducing trimethylation of histone H3 lysine 27 …
through its enzymatic function for inducing trimethylation of histone H3 lysine 27 …
Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
Monoallelic Deletion of BCMA is a frequent feature in multiple myeloma Page 1 American
Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 Phone: 202-776-0544 …
Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 Phone: 202-776-0544 …